Psychedelics Archives - Green Market Report

Video StaffVideo StaffMarch 23, 2020

10min3770

Mental health company Mindbloom provides guided psychedelic therapy treatments using ketamine. The company opened its first location in New York City during the COVID-19 crisis. Mindbloom has quickly pivoted to telemedicine as the demand for its services has risen during the pandemic. Green Market Report was able to speak with Founder Dylan Beynon to discuss the company’s response and its plans for expansion.

Debra Borchardt, Editor, Green Market Report:             Mindbloom is a new company that has a clinic in Manhattan in New York City that is starting ketamine treatments, but they have plans for many more types of treatments using various psychedelic drugs for people with really pressing issues having to do with anxiety, drug-resistant depression. Dyan, tell us how you came up with this idea and what prompted you to start this company.

Dylan Beynon, Founder Mindbloom:                   First super excited to chat with you today, Deb, and to share the incredible work that our psychiatric clinicians are doing in mental health care for people here in New York and soon all across the country. I got the idea for Mindbloom really over the past 10 years. I grew up in a family that had a severe mental illness, both my mother and my sister and throughout my development, getting through some of the turbulence that I grew up with, I turned to psychedelic medicine 10 years ago and it was one of the most transformational events of my life and it’s been a big part of my life for the last 10 years. 18 months ago I became a ketamine patient in a clinical setting and saw that there was an opportunity to take this profound transformational medicine and help bring it to more people and increase access to help people who need it most get the care that they need.

GMR:             And how are you reacting to the current COVID crisis? Because we’ve been hearing that some doctors don’t want to see patients in person right now and with this particular situation, because this virus is so frightening, I would think that your very patients are the ones that really need treatments the most right now, that maybe their anxiety levels have skyrocketed or maybe if they weren’t even an existing patient that, if they weren’t one before, they are one now. How are you guys responding?

Dylan Beynon:                   You nailed it, Deb. We used to say that mental health care is the number one public health crisis in the United States and that’s no longer the case. Coronavirus is without a doubt the number one public health crisis in the United States. We’re in a state of emergency and we’re seeing a demand for treatments for anxiety, depression on Mindbloom a skyrocket since the onset of coronavirus. The way that we’ve responded, and I’m really proud of our clinicians for really feeling the call to service during this time, is we had already begun piloting virtual and remote sessions to help increase access to treatment. So essentially like telepsychedelics. And we had already done through the platform a couple of hundred remote sessions for people who had started their journey in Mindbloom’s nomad center.

Dylan Beynon:                   And so now in response to coronavirus, we are really excited to announce that our clinicians are treating 100% virtually. So remote enabled and guided psychedelic therapy sessions with guided ketamine therapy so that people can stay home and get the treatment that they need for their anxiety and depression without having to come in and keep both our clinicians and clients safe in these tough times.

GMR:             Beyond the inpatient experience, Mindbloom also has special software that you’ve created around the treatment process. Can you dig into that a little bit better? Is that followup software or how does this software relate to the treatment?

Dylan Beynon:                  From day one, we set out to become a technology company, helping use technology to increase access to people and to help our clinicians improve outcomes to help people really get the most out of these treatments. So you can think of it as a teletherapy meets a Headspace platform designed specifically for psychedelic therapy where clients are able to do video consults and video therapy to prepare and integrate their experiences with trained psychiatric clinicians and therapists. Mindbloom also helps people with guided psychedelic therapy content, including audioscapes with guided meditations and music for their sessions and journaling prompts and other content to help them really maximize the experience.

GMR:             One of the things that I know you were planning to do is expand, so right now you mentioned you’re in Manhattan and you’ve got plans to go into other cities. What are those other cities and what are the goals here?

Dylan Beynon:                   In the next 30 days, we’re already going to expand into states that have, in the state of emergency dropped their in-state licensure requirements for physicians and clinicians to need a license in that state to practice. And so that’s an effort to respond to the coronavirus crisis by helping to increase access to behavioral health and mental healthcare treatments. And then we’re going to continue to expand across the country over the next year or two with both our clinic-based and remote-based approaches.

GMR:             And how are you funded? Because you are a new company and expansion is not cheap. And I was just curious, are you self funded? Have you done a raise? What has gotten you to this point?

Dylan Beynon:                   We’re a venture-backed healthcare technology company. We closed our first round of funding in the summer of last year to begin treating our first cohort of clients through the platform and bringing clinicians on to do that treatment. And so we’ve raised funding from some of the biggest investors in healthcare technology and psychedelic medicine. So some of the same people who funded and backed Zocdoc and Oscar and COMPASS Pathways. So right now we’re laser-focused on helping people during this crisis and helping clinicians on Mindbloom add the tools that they need to create these astounding outcomes for people. And I think as long as we continue to do that, then the next funding for expansion will fall in place.

GMR:             Right now you’re really focused on ketamine because that’s legal, but you have plans for Psilocybin and other products, correct?

Dylan Beynon:                   We don’t think of Mindbloom is either a ketamine therapy company nor even a psychedelic medicine company, but as a next-generation mental health and wellbeing platform who are helping to increase access to the most effective science-backed mental health and wellbeing treatments available. Today based on research, based on my experience, based on the experience of our medical director, Dr. Casey Paleos who’s a principal investigator on the MDMA clinical trials and was an early pioneer in ketamine therapy research and practice, we think that ketamine is the most effective science-backed treatment that is not readily or widely available to people. So that’s our focus today, but we are super excited based on everything I just mentioned plus the research for MDMA assisted therapy, which is in phase three clinical trials, Psilocybin assisted therapy, which is in phase two clinical trials. Both breakthrough therapies designation by the FDA as well as other non-psychedelic medicine treatments that we think can be really powerful to help people with anxiety, depression, and other conditions that we begin helping people with.

GMR:             Thank you so much for joining us and good luck with that. And really, I think it’s super that you’re out there helping people, helping them through this crisis and helping them so that they can be functioning adults.


Debra BorchardtDebra BorchardtMarch 10, 2020
Sublingual-Ketamine-1280x853.jpg

5min7160

Psychedelic medicine company Mindbloom has opened its first location in New York City. Located in the NoMad neighborhood of Manhattan, the company is offering. The company has plans to expand rapidly, with a new state-of-the-art flagship space set to open in the city later this year. Additional Mindbloom locations are planned for Los Angeles, San Diego, San Francisco, and Austin.

The treatment at this time offers physician-supervised ketamine treatments. Currently, when it comes to psychedelic medicines, MDMA and psilocybin treatments are still undergoing clinical trials for FDA approval. Ketamine is the only psychedelic medicine that can currently be prescribed in the U.S. The company said that at lower doses, ketamine can induce physical sensations and thought patterns described as psychedelic.

“Psychedelic medicine is increasingly demonstrating that it can provide profound, long-lasting and life-changing effects. We’re helping people achieve a deeper therapeutic experience in order to grow, heal and expand their human potential,” said Dylan Beynon, Mindbloom’s CEO. “We partner with licensed psychiatric clinicians to improve client outcomes by facilitating treatments in a comfortable, elevated, hospitality-inspired space.”

“Mindbloom’s therapy protocols are designed to alleviate suffering for depression or anxiety and facilitate lasting transformation for the people who need it most,” said Dr. Paleos, the company’s Medical Director. “Our programs are backed by extensive medical literature and my own experience researching psychedelic medicine for more than a decade and, more recently, providing ketamine therapy in my private practice.”

How It Works

Mindbloom’s initial offering is guided ketamine therapy, affordably priced at $150 – $250 per session. Prior to booking a session, patients undergo a rigorous initial screening which includes a psychiatric evaluation with a clinician, qualifying clients are prescribed a 4-session program of ketamine therapy administered via sublingual tablet or intramuscular injection. Each session lasts approximately one hour and takes place in a private, spa-like setting with amenities such as zero gravity chairs, weighted blankets, eye masks, noise-canceling headphones and aromatherapy on hand for optimal comfort. Afterward, clients reflect, refresh and journal on their experience in one of Mindbloom’s integration rooms.

Mindbloom has also developed a proprietary software platform to provide patients with customized psychedelic therapy programs and ongoing support throughout their therapeutic journey. In addition to video consultations, clients have access to remote treatment options such as 1:1 virtual integration therapy and coaching, designed to transform clients’ new insights into actionable plans for the day to day life.

The Founders

Paleos has devoted his career to researching ketamine and other psychedelic medicines such as MDMA and psilocybin in both academic and clinical settings. A Co-Principal Investigator for the NYU-Bellevue Ketamine for Depression Study, Dr. Paleos was one of the early researchers to identify ketamine as a breakthrough treatment for depression. Paleos is also a Principal Investigator and Study Therapist for the Multidisciplinary Association for Psychedelic Studies (MAPS)-sponsored MDMA-Assisted Psychotherapy for PTSD Phase 3 Clinical Trials. Previously, he was a Principal Investigator for the MDMA-Assisted Psychotherapy Phase 2 Clinical Trials and a Study Therapist for the NYU Psilocybin Cancer Anxiety Study.

Dylan Beynon is an impact entrepreneur with a track record of building socially conscious technology companies that have positively affected thousands of people across multiple markets. He is Co-founder and Chief Growth Officer at Mighty, a New York microfinance and civil justice company helping plaintiffs in need get a better deal from the justice system.

 

 

 

 

 

 

 

“At Mindbloom, we are democratizing access to psychedelic medicine and destigmatizing the most common, often crippling, mental health conditions,” said Beynon. “It’s our aim to become America’s trusted destination for cutting-edge, science-backed approaches to achieving and maintaining optimal wellness and mental health.”


Anne-Marie FischerAnne-Marie FischerMarch 4, 2020
mushroom.jpg

7min5090

Driven by the leadership of our CEO and founder, Debra Borchardt, Green Market Report is pleased to release the industry’s first psychedelic industry trend report, Trends in Psychedelic Investing, which takes a deep-dive into the emerging movement and the investments and companies to watch behind it.

Our publication had been slowly inching into the emerging psychedelics movement over the last year, profiling various companies such as Orthogonal Thinker and Field Trip Ventures while examining some of the emerging research and perspectives in psychedelics. At the same time, we began creating spaces and occasions for people of the movement to come together to talk about the business of psychedelics, which includes companies that promote and work within the potential of “novel molecules” found in psilocybin (psilocin), DMT, ketamine, MDMA and other substances that are classified as “psychedelic”. 

This past January, Green Market Report hosted the first-ever Psychedelics Summit on the emerging market in New York City. This sold-out event demonstrated the eagerness to grow the psychedelics industry, inspiring the 9-page, 3,500-word Trends in Psychedelic Investing report, which can be downloaded at greenmarketreport.com/reports.

Green Market Report has been the cannabis industry’s central news source on the business and money of cannabis since 2017; our community of reporters covers the global cannabis business, and important initiatives and movements as they unfold. 

As the psychedelics industry and the changing legislation towards certain compounds such as psilocybin develops, we’re observing that many psychedelics pioneers are growing from, or taking their learning from the cannabis industry, making it a natural avenue for our publication. Alongside this, there is growing evidence that psilocybin and other psychedelic compounds will be decriminalized or legalized as more evidence supports the potential benefits of psychedelic-assisted therapies. 

“We have heard from our readers at Green Market Report that there is a great deal of interest in this emerging field of psychedelics and the companies that are leading the way,” said founder Borchardt, “We’re also seeing that some cannabis investors are adding psychedelic investments to their portfolios. As we tried to research this industry, we found that information was lacking, and that is what prompted us to hold our Summit and write this report.”

Trends in Psychedelic Investing takes readers behind the 1960s psychedelics movement led by Timothy Leary and Richard Alpert (later known as Ram Dass) with the advent of the controversial Harvard Psilocybin Project. The report brings us through the journey of the legal status of psychedelics through the decades, with the recent resurgence of the movement gaining steam in the early 2000s. Groups like MAPS (Multidisciplinary Association for Psychedelic Studies) began sponsoring studies that look at the efficacy of psilocybin for Obsessive-Compulsive Disorder. 

The report importantly points out that unlike cannabis, the recreational psychedelics market is relatively small in comparison to the discovered medical and psychological potentials of these compounds. 

The report references several companies within the psychedelics space that are ones to watch as they engage in multi-million capital raises and advance psychedelics research. These companies include Mind Medicine Inc, which anticipates being the first publicly-traded psychedelics pharmaceuticals company; Atai Life Sciences, which is examining psychedelics alongside rapid-acting antidepressant (RAAD) drugs; Eleusis Ltd, which is researching serotonin agonists; Field Trip, which is starting with ketamine therapies; Green Sky Strategies LLC, which is looking at therapeutic adaptogens along with the potentials of microdosing; and Back of the Yards Algae, concerned with developing a safe, sustainable supply of psilocybin that demonstrates good laboratory practice.

Trends in Psychedelic Investing concludes with an important acknowledgment from Green Market Report: unlike the “green rush” that prompted many to pursue cannabis to get rich quick, the investors who are in psychedelics are in it to stay. While we have been excited to see the cannabis movement push forward as the value of cannabinoids is realized, we have every reason to believe that with psychedelics, we are on the brink of a medical revolution.

Stay tuned to Green Market Report’s section on Psychedelics as we continue to release emerging news about this exciting new movement. Our next event on Psychedelic Investing will be held on July 29th in San Francisco. Details will be released soon.

 


Video StaffVideo StaffFebruary 7, 2020

1min5900

The Green Market Report hosted its first Psychedelic Investing conference on January 24, in New York City. This panel was moderated by Lewis Goldberg, Managing Partner at Communications firm KCSA. He was joined by Ronan Levy of Field Trip Ventures and Brian Quigley of Green Sky Strategies. They spoke about the similarities between the emerging psychedelic companies and the early days of the cannabis industry. Levy was at the forefront of the legal cannabis industry in Canada when he co-founded Canadian Cannabis Clinics and CanvasRX Inc, which was acquired by Aurora Cannabis in 2016. His new venture will create clinics that will focus on psychedelics-assisted therapies.  Quigley is the Co-founder of Green Sky Strategies. He and his partners Jim McAlpine and Ophelia Chong have created a Cannabis Strategy team that combines deep cannabis industry and consumer experience with proven Fortune 500 strategic thinking. The group is looking at psychedelic investments. 


Debra BorchardtDebra BorchardtFebruary 6, 2020
field-trip-ventures-squarelogo-1568864504141.png

4min11050

Psychedelic clinic company Field Trip Psychedelics Inc. closed of its oversubscribed Series A financing round. The financing, which was completed through a private placement, raised $8.5 million for the company.

“The interest we had in this financing came from a broad and varied group of academics, entrepreneurs, medical professionals, financial professionals and investment funds,” said Ronan Levy, Executive Chairman of Field Trip. “The ability to pull together such a thoughtful, supportive and diversified investor base is certainly a tribute to the team at Field Trip and the work we are doing. It also speaks profoundly to the level of interest, excitement and importance that people around the world are placing on the advancement of psychedelics and the role they may play in improving mental health, performance, general wellness and happiness.”

The company said the funds will be used to execute the initial stages of Field Trip’s strategic plan to build out the world’s first network of medical centers focused exclusively on psychedelic-enhanced psychotherapy. In addition to that, the financing will help fund the final construction of its research and cultivation facility at the University of the West Indies in Jamaica that is dedicated to the study of psilocybin-producing mushrooms and the discovery of novel therapeutic molecules.

The financing was led by Field Trip’s founders and Singhal Health Foundation. Other notable investors in the round include Subversive CapitalSilver Spike Capital, and the venture capital firm Bolt, as well as individual investors Harris Fricker, an early-stage investor and pioneer in e-payments and blockchain, and Ben Greenfield, a globally recognized longevity expert and biohacker.

“Nearly 1 in 4 people will be diagnosed with a mental health condition in their lifetime. By 2023, depressive disorders will be the single largest cause of the burden of disease globally,” said Sanjay Singhal, Founder of the Singhal Health Foundation. “Addressing the global mental health crisis requires effort, work and coordination from people and organizations of all forms; academic, non-profit and for-profit. The team at Field Trip blends the right balance of a track record of success, ambition, and commitment to ethical and thoughtful business practices, which is why I’m excited to support their efforts and work closely with them to achieve their mission.”


Video StaffVideo StaffFebruary 5, 2020

1min7310

The Green Market Report hosted its first conference on Psychedelic Investing in New York City on January 24. This panel was titled “Business Strategy For Psychedelic Companies.

Journalist Jeremy Berke of Business Insider moderated this panel featuring Atai Life Sciences, which is a global biotech company that was created to address those suffering from mental health disorders. It has created a portfolio including Compass Pathways which uses Psilocybin as its lead compound. The company’s CEO Florian Brand will talk about how they have chosen the companies they have added to their platform and the promising uses of these innovative treatments. He is joined by Shlomi Raz, the founder of Eleusis, a clinical-stage life science company dedicated to unlocking the therapeutic potential of serotonin 2A receptor agonists, commonly referred to as psychedelics, through the mitigation and management of psychoactivity and Dr. Terry Kelly, the CEO of Perception Neurosciences. Thank you for watching the Green Market Report! Subscribe to our channel – it’s Free!


Video StaffVideo StaffFebruary 3, 2020

1min5731

Green Market Report hosted its first Psychedelic Investing Conference on January 24, 2020 in New York City. This is a compilation of still photos from the event. We appreciate everyone who was able to get a ticket to this sold-out event. Thank you to our sponsors: MindMed, Atai Life Sciences, Eleusis Ltd., KCSA Strategic Communications, Green Sky Strategy, Mattio Communications and Field Trip Ventures. Please subscribe to the Green Market Report channel. It’s free!


Video StaffVideo StaffFebruary 3, 2020

1min4510

The Green Market Report sponsored its first conference on Investing in Psychedelic Companies on January 24 in New York City. This panel gave the audience a current read on the marketplace for psychedelics. It was moderated by Shelby Hartman, the Co-Founder, and CEO of Double-Blind Magazine a biannual print magazine and media company that covers timely, untold stories about the expansion of psychedelics around the globe. She was joined by Jay Pleckham and Leonard Leher from Back of the Yards Algae Sciences who spoke about the scalability of growing mushrooms. In addition to that, Lauren Rudick, Partner at Hiller PC discussed the legal environment for manufacturing and testing psychedelics as a result of the lessons learned in cannabis.


StaffStaffJanuary 21, 2020
shutterstock_1526869721-scaled.jpg

3min13400

Just as the psilocybin mushroom market begins to heat up, one enterprising entrepreneur has quickly snapped up the trademark for the word “Psilocybin.” Marijuana Moment picked up on the founder’s notice on LinkedIn that the word had been trademarked. That post has since disappeared and while there is no mention of the trademark happening on the company’s website, the tiny TM does appear after each mention of the word Psilocybin on the company’s website.

The company sells chocolate bars, that don’t seem to contain any mushroom ingredients. In fact, there is little in the way of a description as to how the chocolate is made or sourced. It says the bars “have been created as a gateway to educate you on what is next for medicinal mushroom health and healing.” It does say that all the products are sold out.

Scarlet Ravin describes her company Psilocybin™️ as “a community-based support system holding a sacred knowing for others to come back to their knowing of their God-self.” She describes herself as being “known for her visionary Branding and Marketing which has led her companies to the front of the market allowing multiple press mentions and forward-thinking concepts that grab the attention of the mass market.”

Ravin told Marijuana Moment that she “plans to contribute 10 percent of profits to the Multidisciplinary Association for Psychedelic Studies (MAPS), which is involved in researching the therapeutic benefits of psychedelic substances.”

Marijuana Trademarks Not Allowed

Psilocybin mushrooms are also a schedule 1 substance under the Controlled Substance Act like marijuana. The U.S. Patent Trade Office stated that marijuana is still prohibited from U.S. trademark registration. “The CSA prohibits, among other things, manufacturing, distributing, dispensing, or possessing certain controlled substances, including marijuana. 21 U.S.C. §§812, 841(a)(1), 844(a). Therefore, the USPTO refuses registration when an application identifies goods encompassing CBD or other extracts of marijuana because such goods are unlawful under federal law and do not support valid use of the applied-for mark in commerce.”

Marijuana Moment noted that this trademark is “Specifically for educational materials and it’s listed on the supplemental register, rather than the principal register, which means it would be incumbent upon the brand to prove that it has earned distinctiveness of the mark if the issue went to court.”

 

 

 


Noemi GonzalesNoemi GonzalesJanuary 17, 2020
shutterstock_266222585-scaled.jpg

5min12340

Your Psilocybin Mushroom Companion: An Informative, Easy-to-Use Guide to Understanding Magic Mushrooms―From Tips and Trips to Microdosing and Psychedelic Therapy

Your Psilocybin Mushroom Companion” by Michelle Janikian is a useful book when it comes to shedding light on the benefits and misconceptions of mushroom/Psilocybin use. The level of information available is quite surprising and it does a great job of diffusing lingering myths on the subject of Psilocybin.

Not sure if you want the book just yet?

No worries, we reviewed it for you!

-Topic Focus-

The author, Michelle Janikian, focuses on the implementation side of mushroom use. Here you will find information about the best ways to guide others during their psychedelic trips, microdosing, how to maximize mental health benefits, and more.

There is much misinformation on this subject so seeing some focus allotted toward the dispelling of such myths in “Your Psilocybin Mushroom Companion” is refreshing.

Reading about the notion that mushrooms can improve your life in a variety of ways is certainly interesting. The discussion on the benefits gained from microdosing is impressive and learning how to guide others seems to be a useful skill.

Reading about how microdosing can increase physical stamina, boost your mood, and elevate your clarity of thought is very fascinating and worth further exploration.

About the Author

Michelle Janikian is a journalist/author who has experience writing for publications such as Rolling Stone, High Times, Teen Vogue, and currently writes for Playboy.

Michelle studied writing and psychology at Sarah Lawrence College and the majority of her writing content focuses on drug policy, education, and the growing legal cannabis industry. Her passion for these subjects becomes clear as you read her content.

She also displays expertise in investigating the potential medicinal benefits of plants/substances that currently possess a degree of social stigma.

Michelle was raised in New Jersey but she was born in New York.

You can learn more about the author at michellejanikian.com

-Reading Experience-

The writing level is very appropriate and welcoming for beginners to begin to understand microdosing, mushroom use, and more.

You do not need to be up to speed on deep scientific terminology to keep up with and utilize this book. Again, this is a great book for the beginner to learn about the introductory topics to Psilocybin use and to dispel potential misconceptions on the topic.

There is minimal fluff so the book gets right to the point and flows well. It should not take more than a few days to get through and makes for a great reference guide to look back to when needed.

It is kind of exciting to consider the potential implications in the future that Psilocybin could have on the medical industry after reading this book.

-Summary-

“Your Psilocybin Mushroom Companion” is an ideal tool for a beginner to understand the basics of microdosing, dispelling myths, and learning about the potential benefits that come with microdosing Psilocybin mushrooms.

The book is to the point, accessible, and is a quick read. No advanced scientific degrees required to keep up with this one.

The author does a great job of demonstrating her expertise on the topic as she guides us through some useful information on Psilocybin mushrooms and their implementation.

You can see for yourself how Psilocybin can benefit your life by checking out Michelle’s book here:

https://www.amazon.com/Your-Psilocybin-Mushroom-Companion-Easy/dp/1612439470



About Us

The Green Market Report focuses on the financial news of the rapidly growing cannabis industry. Our target approach filters out the daily noise and does a deep dive into the financial, business and economic side of the cannabis industry. Our team is cultivating the industry’s critical news into one source and providing open source insights and data analysis


READ MORE



Recent Tweets

@GreenMarketRpt – 2 days

$HRVSF $HARV ⁦@HarvestHOC⁩ Health Buys Franklin Labs, Lays Off Have A Heart Employees ⁦@haveaheart502⁩

@GreenMarketRpt – 2 days

$ZDPY ⁦@ZonedProperties⁩ Reports Increase In Revenue For 2019, Expenses Fall #cannabis…

@GreenMarketRpt – 2 days

RT : Companies Step Up To Help During Pandemic ⁦@Cloudious9Crew⁩ ⁦@Moxie710⁩ ⁦⁦@bluebirdhemp⁩ ⁦@SOLARISFarm⁩ ⁦@moonmoth…

Back to Top

You have Successfully Subscribed!